Double-blind Abatacept ( DrugBank: Abatacept )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00048932 (ClinicalTrials.gov) | December 2002 | 11/11/2002 | A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Double-blind Abatacept;Drug: Double-blind Placebo;Drug: Open-label Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 1795 | Phase 3 | United States |